U.S. markets closed
  • S&P Futures

    3,285.75
    +22.25 (+0.68%)
     
  • Dow Futures

    26,598.00
    +189.00 (+0.72%)
     
  • Nasdaq Futures

    11,200.00
    +67.25 (+0.60%)
     
  • Russell 2000 Futures

    1,548.30
    +9.10 (+0.59%)
     
  • Crude Oil

    37.60
    +0.21 (+0.56%)
     
  • Gold

    1,880.10
    +0.90 (+0.05%)
     
  • Silver

    23.50
    +0.14 (+0.60%)
     
  • EUR/USD

    1.1755
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    0.7810
    +0.0030 (+0.39%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.2993
    +0.0006 (+0.05%)
     
  • USD/JPY

    104.3010
    0.0000 (0.00%)
     
  • BTC-USD

    13,297.51
    +39.83 (+0.30%)
     
  • CMC Crypto 200

    262.80
    -9.89 (-3.63%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,418.51
    0.00 (0.00%)
     

FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

NEW YORK, NY / ACCESSWIRE / April 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Akorn, Inc. (AKRX)
Class Period: August 1, 2018 - January 8, 2019
Deadline: April 22, 2019
For more info: www.bgandg.com/akrx

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Akorn's management misled investors concerning the severity of Akorn's manufacturing violations at its Decatur, Illinois facility; (2) Akorn's responses to the Food and Drug Administration's ("FDA") Form 483 - which contained a list of observations made by the FDA during its inspection of Akorn's Decatur, Illinois facility in April and May 2018 - would be deemed inadequate by the FDA; (3) Akorn repeatedly failed to correct manufacturing violations at this facility; (4) the foregoing would subject Akorn to heightened regulatory scrutiny by the FDA; and (5) as a result, Akorn's public statements were materially false and misleading at all relevant times.

Health Insurance Innovations, Inc. (HIIQ)
Class Period: February 28, 2018 - November 27, 2018
Deadline: April 22, 2019
For more info: www.bgandg.com/hiiq

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) a substantial portion of Health Insurance Innovations' revenue was derived from third parties; (2) these third parties used deceptive tactics to sell Health Insurance Innovations' policies, including overstating the policy's coverage and/or selling under the licenses of employees who had no involvement in the underlying sales; (3) regulatory scrutiny of these third parties would materially impact Health Insurance Innovations' operations; and (4) as a result of the foregoing, defendants' positive statements about Health Insurance Innovations' business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Amarin Corporation (NASDAQ: AMRN)
Class Period: September 24, 2018 - November 8, 2018
Deadline:
April 23, 2019
For more info:
www.bgandg.com/amrn

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com:
https://www.accesswire.com/539933/FINAL-DEADLINE--AKRX-HIIQ-AMRN--Bronstein-Gewirtz-Grossman-LLC